International partners considering a China or Hainan manufacturing route should separate policy opportunity from project readiness. A public measure can explain the direction of a regulatory environment; only a product-specific review can establish whether a proposed programme should progress.
1. What the public measures say
Hainan’s medicines regulator has published measures aimed at supporting the conversion of imported innovative drugs and improved new drugs into local development and manufacturing activity. The notice discusses the Lecheng research-and-use setting, possible use of qualifying real-world data, early planning for production facilities, use of overseas technical materials where applicable, and related support arrangements. [1]
A subsequent regulator meeting described the broader “Lecheng research-and-use + Hainan manufacturing” model, including work on regulatory pathways, contract R&D, segmented production and shared manufacturing as possible ecosystem directions. [2]
2. What this policy context does not decide
- It does not establish that Hainan Hailing—or any other company—has received project approval, policy support or a manufacturing assignment.
- It does not prove that a particular product can be transferred, registered, manufactured or launched within a stated period.
- It does not replace a review of the legal entity, manufacturing scope, quality system, technical package, target market, supply model or commercial terms.
3. Four questions an international partner should ask first
| Decision area | Question to clarify | Evidence needed before commitment |
|---|---|---|
| Product and market | Which market, product lifecycle stage and registration route are intended? | Public product context followed by controlled regulatory review. |
| Legal and technical route | Who owns the dossier, key process knowledge and decision rights? | A defined responsibility model and a controlled transfer plan. |
| Receiving site fit | Can the proposed site be responsibly assessed for the product and process? | Facility, equipment, validation, co-line and quality-risk evidence. |
| Governance and supply | How will quality, changes, release, timelines and supply decisions be managed? | Project governance, quality-agreement principles and a realistic stage plan. |
4. Why contract manufacturing discipline remains essential
China’s NMPA states that a contract manufacturer should evaluate the MAH and proposed product before accepting a project, including qualifications, quality-management capability, technical-transfer feasibility and co-line manufacturing risk. The same announcement requires defined quality responsibilities, risk communication, change control and traceable records. [3]
For sterile drugs, the announcement sets additional conditions and experience expectations. These are regulatory requirements and project-level considerations; they should not be reduced to a marketing label or inferred from a general dosage-form statement.
5. A responsible first step
Before an NDA, a potential partner can provide a concise non-confidential brief: organisation, dosage form and presentation, target market, project stage, requested model (CMO, CDMO, technology transfer or registration cooperation), broad timing and the decision sought. Formulae, complete dossiers, detailed process parameters, patient information, audit files and trade secrets should not be exchanged at this stage.
Primary public sources
- Hainan Medical Products Administration: Measures Supporting the Local Conversion of Imported Innovative and Improved New Drugs
- Hainan Medical Products Administration: Meeting on the “Lecheng research-and-use + Hainan manufacturing” model
- NMPA Announcement No. 134 of 2025 on Contract Manufacturing of Drugs
This page is a source-based public policy interpretation for general business discussion. It is not legal, regulatory, investment or medical advice, and does not constitute an offer, capacity reservation, project acceptance or statement of eligibility for any policy or programme.